Ilypsa

Ilypsa, Inc. operated as a biopharmaceutical company with a sharp focus on developing treatments for renal disorders. Founded in 2002 and formerly known as Symyx Therapeutics, the company established its headquarters in Santa Clara, California. Ilypsa's core business was centered on the discovery and development of non-absorbed polymeric drugs aimed at managing complications associated with chronic kidney disease (CKD).

The company's flagship product candidate was ILY101, an orally administered, non-absorbed polymeric agent. This drug was designed as a phosphate binder to treat hyperphosphatemia, a condition characterized by elevated phosphate levels in the blood, which is common in CKD patients undergoing hemodialysis. ILY101 worked by binding to dietary phosphate within the gastrointestinal tract, thereby preventing its absorption into the bloodstream. The product had successfully completed Phase 2 clinical trials, demonstrating its potential as a therapeutic option.

A significant milestone in the company's history occurred in June 2007, when Amgen (NASDAQ: AMGN) announced its agreement to acquire Ilypsa for approximately $420 million in cash. The acquisition was finalized in July 2007, and Ilypsa became a wholly-owned subsidiary of Amgen. This strategic acquisition was intended to bolster Amgen's nephrology portfolio. Following the acquisition, key members of the Ilypsa management team, including CEO Jay Shepard, went on to form a spin-out company called Relypsa, Inc., which continued to work on polymeric drugs.

Keywords: Ilypsa, biopharmaceutical, renal disorders, chronic kidney disease, ILY101, hyperphosphatemia, phosphate binder, Amgen acquisition, polymeric drugs, nephrology, Symyx Therapeutics, Jay Shepard, kidney disease treatment, non-absorbed polymers, clinical trials, pharmaceutical development, Santa Clara startup, renal care